Melanoma — Trials · CancerIndex

Clinical trials

Registered studies

3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 605
Recruiting: 316
Ph III recruiting: 30
Growth YoY: +37.2%
Industry share: 33%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 37.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (571)

clinicaltrialsPublishedShowing 151–200 of 1,379 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06365619	Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma(NeoRelapse)	recruiting	Phase 2	25	University of UtahOTHER	1	Jul 2, 2026	clinicaltrials
NCT07671495	Adjuvant Therapy of Skin Melanoma With Alpha Interferon and Naderin(ATSMAIN)	completed	Phase 2	278	MIPO ClinicOTHER	0	Jun 30, 2026	clinicaltrials